首页> 外文OA文献 >Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer

【2h】

Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer

机译：他莫昔芬抗性的机制：雌激素受体 - HER2 / NEU串扰在ER / HER2阳性乳腺癌中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
J. Shou; S. Massarweh; C. K. Osborne; A. E. Wakeling; S. Ali; H. Weiss; R. Schiff;
展开▼
作者单位

展开▼
年度 2004
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2eu cross-talk in ER/HER2-positive breast cancer. [J] . Shou J, Massarweh S, Osborne CK, Journal of the National Cancer Institute . 2004,第12期

机译：他莫昔芬抗性的机制：ER / HER2阳性乳腺癌中雌激素受体-HER2 / neu串扰增加。
2. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. [J] . Osborne CK, Schiff R The Breast : . 2003,第6期

机译：生长因子受体与雌激素受体的相互作用是乳腺癌中他莫昔芬耐药的机制。
3. Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors [J] . Jamie N Mills, Alex C Rutkovsky, Antonio Giordano Current opinion in pharmacology . 2018,第期

机译：雌激素受体阳性乳腺癌耐药机制：克服毒素/芳香酶抑制剂的耐药性
4. Study on Molecular Docking of Red Betel (Piper Crocatum Ruiz Pav.) Active Compound and Tamoxifen Drug as an Inhibitor of Estrogen Receptor-α (ER-α) that Plays a Role in Breast Cancer [C] . Siti Imroatul Maslikah, Sri Rahayu Lestari, Nursasi Handayani, International Conference on Life Sciences and Technology . 2020

机译：红色槟榔（吹笛茶叶ruiz＆pav.）活性化合物和三氧化物药物作为发挥乳腺癌作用的雌激素受体-α（ER-α）抑制剂的研究
5. Mechanisms of estrogen receptor (ER) action in breast cancer cells: Role of ER AF-1 domain in ER/SP-1 transactivation and modulation of ER by the ring finger coactivator SNURF. [D] . Saville, Bradley Martin. 2002

机译：乳腺癌细胞中雌激素受体（ER）作用的机制：ER AF-1域在无名指辅助激活剂SNURF的ER / SP-1反式激活和ER调节中的作用。
6. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance [O] . Jing Feng, Ti Wen, Zhi Li, 2020

机译：ER途径和LNCRNA MAFG-AS1 / miR-339-5P / CDK2轴之间的串扰促进了ER +乳腺癌的进展并赋予他莫莫毒性的抗性
7. Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptor–Positive, HER-2/neu-Positive Breast Cancer [O] . Suleiman Massarweh, C. Kent Osborne, Shou Jiang, 2006

机译：患有雌激素受体阳性，HER-2 / Neu阳性乳腺癌模型中患者抗剥离和抗雌激素剥夺和氟斯坦的机制
8. Design, Synthesis, and Evaluation of Estrogen Sulfotransferase Inhibitors: Potential Enhancers of Tamoxifen-Mediated Apoptosis in ER Negative Breast Cancers [R] . Peterson, B. R. 2002

机译：雌激素磺基转移酶抑制剂的设计，合成和评价：他莫昔芬介导的ER阴性乳腺癌细胞凋亡的潜在增强剂

Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅